Centerpoint Advisors LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Centerpoint Advisors LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,500 shares of the medical equipment provider’s stock, valued at approximately $224,000.

A number of other hedge funds have also made changes to their positions in LNTH. GAM Holding AG acquired a new position in shares of Lantheus in the fourth quarter worth $588,000. Venturi Wealth Management LLC boosted its holdings in shares of Lantheus by 60.0% in the 4th quarter. Venturi Wealth Management LLC now owns 3,625 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 1,359 shares during the last quarter. Sanctuary Advisors LLC grew its position in Lantheus by 58.5% during the fourth quarter. Sanctuary Advisors LLC now owns 18,042 shares of the medical equipment provider’s stock valued at $1,674,000 after acquiring an additional 6,656 shares during the period. State of New Jersey Common Pension Fund D increased its position in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after purchasing an additional 115 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Lantheus by 1.5% during the fourth quarter. Rhumbline Advisers now owns 212,673 shares of the medical equipment provider’s stock worth $19,026,000 after buying an additional 3,136 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $79.94 on Tuesday. Lantheus Holdings, Inc. has a 1-year low of $56.06 and a 1-year high of $126.89. The company has a market capitalization of $5.56 billion, a P/E ratio of 13.30 and a beta of 0.44. The business’s fifty day moving average price is $91.17 and its two-hundred day moving average price is $97.53.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.